ScoreWhy is Windlas Biotech Ltd ?
1
The company is Net-Debt Free
2
Poor long term growth as Operating profit has grown by an annual rate 12.14% of over the last 5 years
3
Flat results in Mar 26
- ROCE(HY) Lowest at 14.90%
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 1.81 cr
4
With ROE of 11.4, it has a Fair valuation with a 3 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -10.70%, its profits have risen by 8.9% ; the PEG ratio of the company is 2.6
5
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 0.7% over the previous quarter and collectively hold 11.89% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
6
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 3.58% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -10.70% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Windlas Biotech should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Windlas Biotech for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Windlas Biotech
-5.38%
-0.33
32.59%
Sensex
-2.3%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
16.15%
EBIT Growth (5y)
12.14%
EBIT to Interest (avg)
32.88
Debt to EBITDA (avg)
0.16
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
1.33
Tax Ratio
23.59%
Dividend Payout Ratio
19.93%
Pledged Shares
0
Institutional Holding
11.89%
ROCE (avg)
21.76%
ROE (avg)
11.33%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
37
Price to Book Value
3.04
EV to EBIT
20.66
EV to EBITDA
14.60
EV to Capital Employed
4.42
EV to Sales
1.69
PEG Ratio
2.57
Dividend Yield
0.74%
ROCE (Latest)
21.40%
ROE (Latest)
11.44%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET SALES(Q)
Highest at Rs 238.50 cr
-3What is not working for the Company
ROCE(HY)
Lowest at 14.90%
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 1.81 cr
Loading Valuation Snapshot...
Here's what is working for Windlas Biotech
Net Sales - Quarterly
Highest at Rs 238.50 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Here's what is not working for Windlas Biotech
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 1.81 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
